Tmunity Therapeutics is a private clinical stage biotherapeutics company delivering the full potential of next-generation T cell immunotherapy to more patients with devastating diseases. Integrating broad collaborations with the University of Pennsylvania (UPenn) and the University of Minnesota (UMinn) with the groundbreaking scientiﬁc, clinical and manufacturing expertise and demonstrated track record of its founders, Tmunity represents a new center of gravity in translational T cell medicine. The company is developing a diversiﬁed portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body. These personalized next-generation immunotherapies for cancer, infectious disease and autoimmune disease are advancing rapidly toward the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at UPenn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of T cell therapies.